GZ389988 / Sanofi - LARVOL DELTA

Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. (PubMed, Osteoarthritis Cartilage) - P2 | "IA injection of TrkA inhibitor GZ389988A in knee OA subjects reduced pain with a numerically functional gain and an acceptable safety profile. (ClinicalTrials.gov, NCT02845271)."

Clinical • Journal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Genzyme, a Sanofi Company; N=24 ➔ 40

Enrollment change • Biosimilar • Immunology • Inflammation • Osteoarthritis • Pain